Valuation: StemCells Inc

Market Cap 90.67M 79.24M 74.47M 67.96M 128M 8.67B 128M 894M 345M 4.43B 341M 333M 14.27B P/E 2026 *
-4.5x
P/E 2027 * -4.71x
Enterprise Value 90.67M 79.24M 74.47M 67.96M 128M 8.67B 128M 894M 345M 4.43B 341M 333M 14.27B EV / Sales 2026 *
50.4x
EV / Sales 2027 * 8.89x
Free-Float
100%
Yield 2026 *
-
Yield 2027 * -
08-14 B. Riley Adjusts Price Target on Microbot Medical to $4 From $5, Maintains Buy Rating MT
08-11 Microbot Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-11 Microbot Medical Inc. Announces Revenue Results for the Second Quarter Ended June 30, 2026 CI
06-23 Microbot Medical Announces First Health System in Pennsylvania to Adopt the Liberty Endovascular Robotic System CI
06-16 Microbot Medical Inc. Enters Into Agreement With Lovell Government Services To Expand Access For America?s Veteran And Military Patient Populations CI
06-16 Microbot Medical Enters Agreement Expanding Access to Federal Healthcare Systems MT
06-09 Microbot Medical Inc. Announces A Notable Health System as the First in Michigan to Adopt the Liberty Endovascular Robotic System CI
06-02 Microbot Medical Inc. Secures First North Carolina Healthcare System to Adopt the LIBERTY Endovascular Robotic System CI
05-26 Microbot Medical Inc. Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY Endovascular Robotic System CI
05-19 Microbot Medical Inc. - Shareholder/Analyst Call
05-14 Microbot Medical recorded revenue during its quarter ended March 31, benefiting from limited market release of Liberty System RE
05-14 Microbot Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-05 Microbot Medical®'s Liberty® endovascular robotic system is now adopted by multiple accounts across key territories including two Access-PVI pivotal clinical trial sites RE
Manager TitleAgeSince
Chief Executive Officer 54 02/08/1988
Director of Finance/CFO 47 01/04/2022
Chief Operating Officer - 21/01/2025
Director TitleAgeSince
Chairman 54 01/01/2013
Director/Board Member 61 28/11/2016
Director/Board Member 65 06/02/2017
Change 5-day change 1-year change 3-year change Capi.($)
-19.35%+575.21% - - 90.67M
+2.55%+4.77%+4.07%+32.02% 46.68B
+0.37%+0.58%+44.40%+36.47% 44.42B
-0.21%-6.38%+331.87%+539.32% 41.32B
+0.30%+5.53%+8.24%+91.86% 41.58B
-1.60%-0.17%+9.73%+43.63% 30.14B
+0.47%+1.75%+26.76%+160.15% 17.42B
-0.56%-1.51% - - 15.6B
+1.15%+7.46%+25.97%+43.93% 15.54B
-0.48%+13.28%-9.18% - 14.08B
Average -1.70%+3.39%+55.23%+135.34% 29.64B
Weighted average by Cap. +0.42%+1.94%+68.68%+143.42%

Financials

2026 *2027 *
Net sales 1.8M 1.57M 1.48M 1.35M 2.53M 172M 2.53M 17.73M 6.84M 87.81M 6.75M 6.61M 283M 10.2M 8.91M 8.38M 7.65M 14.35M 975M 14.35M 101M 38.8M 498M 38.31M 37.47M 1.61B
Net income -20.43M -17.86M -16.78M -15.31M -28.74M -1.95B -28.75M -201M -77.72M -998M -76.73M -75.05M -3.22B -19.42M -16.97M -15.95M -14.56M -27.32M -1.86B -27.33M -191M -73.88M -948M -72.94M -71.34M -3.06B
Net Debt - -
Logo StemCells Inc
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!